Page last updated: 2024-12-06

coformycin

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Cross-References

ID SourceID
PubMed CID25447
CHEBI ID16213
SCHEMBL ID442534
MeSH IDM0004720

Synonyms (21)

Synonym
(r)-3,4,7,8-tetrahydro-3-beta-d-ribofuranosylimidazo(4,5-d)(1,3)diazepin-8-ol
CHEBI:16213 ,
(8r)-3-beta-d-ribofuranosyl-3,6,7,8-tetrahydroimidazo[4,5-d][1,3]diazepin-8-ol
imidazo(4,5-d)(1,3)diazepin-8-ol, 3,4,7,8-tetrahydro-3-beta-d-ribofuranosyl-, (r)-
nsc-277817
C01677
11033-22-0
COFORMYCIN ,
imidazo[4,5-d][1,3]diazepin-8-ol, 3,4,7,8-tetrahydro-3-.beta.-d-ribofuranosyl-, (8r)
(2r,3r,4s,5r)-2-[(8r)-8-hydroxy-7,8-dihydro-6h-imidazo[4,5-d][1,3]diazepin-3-yl]-5-(hydroxymethyl)tetrahydrofuran-3,4-diol
(2r,3r,4s,5r)-2-[(8r)-8-hydroxy-7,8-dihydro-4h-imidazo[4,5-d][1,3]diazepin-3-yl]-5-(hydroxymethyl)oxolane-3,4-diol
e49510zl0h ,
unii-e49510zl0h
bdbm50367032
SCHEMBL442534
imidazo(4,5-d)(1,3)diazepin-8-ol, 3,4,7,8-tetrahydro-3-.beta.-d-ribofuranosyl-, (8r)-
YOOVTUPUBVHMPG-LODYRLCVSA-N
Q27098587
HY-117260
CS-0064597
AKOS040745679

Research Excerpts

Overview

Deoxycoformycin (DCF) is a tight-binding inhibitor of adenosine deaminase (ADA) currently undergoing phase I--II evaluation. Deoxyco formycin is a potent ADA inhibitor and has been shown to be active in acute lymphoblastic leukemia at high doses.

ExcerptReferenceRelevance
"Coformycin, which is a competitive inhibitor of adenosine deaminase, did not potentiate adenosine action."( Suppression by adenine compounds of histamine-induced contraction in isolated guinea pig tracheal rings.
Miyamoto, T; Nishida, Y; Suzuki, S, 1982
)
0.99
"Deoxycoformycin (DCF) is an inhibitor of adenosine deaminase (ADA). "( Clinical pharmacology of deoxycoformycin.
Agarwal, RP; Kufe, DW; Major, PP, 1981
)
1.07
"Deoxycoformycin is a potent inhibitor of adenosine deaminase and would be expected to elevate the levels of adenosine in the central nervous system."( Hypnotic effects of deoxycorformycin in rats.
Djuricic-Nedelson, M; Green, RD; Radulovacki, M; Virus, RM, 1983
)
0.72
"Deoxycoformycin (DCF) is a tight-binding inhibitor of adenosine deaminase (ADA) currently undergoing phase I--II evaluation. "( Deoxycoformycin: neurological toxicity.
Agarwal, RP; Kufe, DW; Major, PP, 1981
)
1.29
"Deoxycoformycin (dCF) is a specific inhibitor of adenosine deaminase (ADA). "( Isolation of deoxycoformycin-resistant cells with increased levels of adenosine deaminase.
Chiang, J; Hoffee, PA; Hunt, SW, 1982
)
1.11
"Isocoformycin is a structural isomer of coformycin which has been demonstrated to be a potent inhibitor of adenosine deaminase. "( Studies on inhibition of adenosine deaminase by isocoformycin in vitro and in vivo.
Kumada, Y; Shimazaki, M; Takeuchi, T; Umezawa, H; Watanabe, K, 1979
)
1.13
"Deoxycoformycin is a potent ADA inhibitor and has been shown to be active in acute lymphoblastic leukemia at high doses but associated with unpredictable toxicity."( Pentostatin (2'deoxycoformycin) for the treatment of lymphoid neoplasms.
Blanc, CM; Cataldo, F; Derossi, G; Ho, AD; Kuse, R; Lauria, F; McVie, G; Stryckmans, P; Thaler, J; Willemze, R, 1989
)
1.06
"Deoxycoformycin (dCF) is a promising new antineoplastic agent in the treatment of lymphoid malignancies, particularly hairy cell leukemia (HCL). "( Hypersensitivity reactions to deoxycoformycin.
Eisenhauer, E; Grem, JL; Hoth, DF; King, SA; O'Dwyer, PJ, 1989
)
1.07
"Deoxycoformycin (DCF) is a specific inhibitor of adenosine deaminase (ADA) and has been shown to be active in lymphoid neoplasms. "( Enzyme activities of leukemic cells and biochemical changes induced by deoxycoformycin in vitro--lack of correlation with clinical response.
Dietz, G; Ganeshaguru, K; Ho, AD; Hoffbrand, AV; Hunstein, W; Knauf, W; Trede, I, 1989
)
1.02
"Coformycin, which is an inhibitor of adenosine deaminase, significantly inhibited in vitro blastogenic responses of human lymphocytes to both phytohaemagglutinin (PHA) and pokeweed mitogen (PWM), whereas blastogenic responses to bacterial lipopolysaccharide (LPS) were rather enhanced by the addition of coformycin. "( Purine metabolic enzymes in lymphocytes. IV. Effects of enzyme inhibitors and enzyme substrates on the blastogenic responses of human lymphocytes.
Akuzawa, Y; Kurashige, S; Mitsuhashi, S, 1985
)
1.71

Treatment

Coformycin treatment had no effect on thrombin-stimulated lactate production, even when oxidative phosphorylation was blocked by antimycin A. For coformYcin-treated mice, spleen leucocyte and thymocyte response to concanavalin A (Con A) was reduced to 20 and 60% of controls respectively.

ExcerptReferenceRelevance
"Deoxycoformycin pretreatment had no effect on macrophages or B cells; however, pretreatment of the T cells resulted in increased antibody responses."( Inhibition of adenosine deaminase leads to enhanced antibody responses in the mouse.
Gordon, DS; McDougal, JS; Nicholson, JK, 1983
)
0.72
"Coformycin treatment had no effect on thrombin-stimulated lactate production, even when oxidative phosphorylation was blocked by antimycin A, nor on the rate of thrombin-stimulated glycogenolysis."( Coformycin inhibition of platelet AMP deaminase has no effect on thrombin-induced platelet secretion nor on glycolysis or glycogenolysis.
Ashby, B; Holmsen, H; Wernick, E, 1983
)
2.43
"For coformycin-treated mice, spleen leucocyte and thymocyte response to concanavalin A (Con A) was reduced to 20 and 60% of controls respectively."( S-adenosylhomocysteine hydrolase activity, deoxyadenosine triphosphate accumulation, and competence of thymocyte and spleen leucocyte response to mitogens in coformycin-treated mice.
Lukey, T; Snyder, FF, 1983
)
0.94

Toxicity

ExcerptReferenceRelevance
"Deoxyadenosine has been implicated as the toxic metabolite causing profound lymphopenia in immunodeficient children with a genetic deficiency of adenosine deaminase (ADA), and in adults treated with the potent ADA inhibitor deoxycoformycin."( Mechanism of deoxyadenosine and 2-chlorodeoxyadenosine toxicity to nondividing human lymphocytes.
Carrera, CJ; Carson, DA; Kubota, M; Seto, S; Wasson, DB, 1985
)
0.45
" If dATP is the toxic metabolic accumulated in the malignant cells of patients treated with dCf, we propose that AdR supplementation of treatment should be considered with extreme caution since severe damage to normal tissues might result."( Toxicity and immunosuppressive activity of binary combinations of 2'-deoxycoformycin and 2'-deoxyadenosine.
Clink, HM; Harrap, KR; Kohn, J; McGhee, KG; Neville, AM; Paine, RM; Weston, BJ,
)
0.36
" Deoxyadenosine was the most toxic in all the systems, the LD50 values being 20-25 microM."( Adenosine and deoxyadenosine toxicity in colony assay systems for human T-lymphocytes, B-lymphocytes, and granulocytes.
Belch, A; Brox, LW; Pollock, E, 1982
)
0.26

Pharmacokinetics

ExcerptReferenceRelevance
" Pharmacokinetic parameters are determined by a sequential optimization scheme in which each tissue is studied by means of a hybrid model."( Physiologic model for the pharmacokinetics of 2'deoxycoformycin in normal and leukemic mice.
Dedrick, RL; King, FG, 1981
)
0.51

Compound-Compound Interactions

The biologic effects of a series of sugar-substituted analogs of tubercidin were evaluated and compared with the effects of the homologous series of adenosine analogs in combination with 2'-deoxycoformycin.

ExcerptReferenceRelevance
" The activity of 9-beta-D-arabinofuranosyladenine 5'-monophosphate, alone or in combination with either of the two inhibitors of adenosine deaminase, was comparable to that of 9-beta-D-arabinofuranosyladenine (ara-A), apparently reflecting the rapid conversion of 9-beta-D-arabinofuranosyladenine 5'-monophosphate to ara-A by L1210/C2 cells."( Antiproliferative effects of 9-beta-D-arabinofuranosyladenine 5'-monophosphate and related compounds in combination with adenosine deaminase inhibitors against mouse leukemia L1210/C2 cells in culture.
Cass, CE; Selner, M; Tan, TH, 1979
)
0.26
"The toxicology and pharmacology of formycin both as a single agent and combined with the adenosine deaminase inhibitor 2'-deoxycoformycin (dCF) were examined in outbred Swiss mice heterozygous for the nude gene (nu/+)."( Biochemical pharmacology and toxicology of formycin alone and in combination with 2'-deoxycoformycin (pentostatin).
Calabresi, P; Chu, SH; Crabtree, GW; Dexter, DL; Diamond, I; Farineau, DM; Ghoda, LY; McGowan, DL; Parks, RE; Spremulli, EN, 1983
)
0.69
"Pentostatin (I), a tight-binding inhibitor of adenosine deaminase, was evaluated in combination with the partially effective antitumor nucleoside N6-(delta 2-isopentenyl)adenosine (II) for cytotoxic activity against cultured L-1210 lymphocytic mouse leukemia cells."( Increased cytotoxicity of N6-(delta 2-isopentenyl)adenosine in combination with pentostatin against L-1210 leukemia cells.
Chang, Y; Hacker, B, 1983
)
0.27
"The biologic effects of a series of sugar-substituted analogs of tubercidin were evaluated and compared with the effects of the homologous series of adenosine analogs in combination with 2'-deoxycoformycin."( Comparison of the effects on cultured L1210 leukemia cells of the ribosyl, 2'-deoxyribosyl, and xylosyl homologs of tubercidin and adenosine alone or in combination with 2'-deoxycoformycin.
Cass, CE; Muhs, WH; Robins, MJ; Selner, M; Tan, TH, 1982
)
0.65
"The toxicology and metabolism of 8-azaadenosine (8-azaAdo) were examined both as a single agent and in combination with the adenosine deaminase inhibitor, 2'-deoxycoformycin (dCF)."( Biochemical pharmacology and toxicology of 8-azaadenosine alone and in combination with 2'-deoxycoformycin (pentostatin).
Calabresi, P; Chu, SH; Crabtree, GW; Dexter, DL; Diamond, I; Farineau, DM; Ghoda, LY; McGowan, DL; Parks, RE; Spremulli, EN, 1982
)
0.68

Dosage Studied

Dose-response analysis demonstrated that the concentration of deoxycoformycin at which there was 50% inhibition of growth was greater than 1 X 10(-3) M in lymphoblastoid cells. Dosage appeared to have no effect on the rate of recovery but marked tissue differences were observed.

ExcerptRelevanceReference
" Further investigations of antitumor efficacy with the use of this low dosage schedule should continue in patients with hematologic neoplasms, and additional preliminary studies of the combination of an adenosine deaminase inhibitor with an adenosine analog should also be considered."( Clinical, pharmacologic, and immunologic effects of 2'-deoxycoformycin.
Calabresi, P; Crabtree, GW; Cummings, FJ; Parks, RE; Spremulli, EN; Wiemann, MC, 1988
)
0.52
" Cells were treated in a dose-response manner for 72 hr and the concentration of drug necessary to inhibit cell growth 50% (GI50) was determined."( Differential antiproliferative actions of 2',5' oligo A trimer core and its cordycepin analogue on human tumor cells.
Hubbell, HR; Lee, C; Pequignot, EC; Suhadolnik, RJ; Willis, DH, 1985
)
0.27
" None of the dosing regimens had any effect on anticollagen antibody titer."( Effects of pentostatin (2'deoxycoformycin), an inhibitor of adenosine deaminase, on type II collagen-induced arthritis in rats.
Gilbertsen, RB, 1985
)
0.56
" This effect could be important in vivo where levels of ara-A oscillate with dosing schedule."( Metabolism of arabinosyladenine in herpes simplex virus-infected and uninfected cells. Correlation with inhibition of DNA synthesis and role in antiviral selectivity.
Drach, JC; Novack, J; Schwartz, PM; Shipman, C, 1984
)
0.27
" A dose-response analysis demonstrated that the concentration of deoxycoformycin at which there was 50% inhibition of growth was greater than 1 X 10(-3) M in lymphoblastoid cells."( In vitro metabolism of deoxycoformycin in human T lymphoblastoid cells. Phosphorylation of deoxycoformycin and incorporation into cellular DNA.
Coleman, MS; Siaw, MF, 1984
)
0.8
" Dosage appeared to have no effect on the rate of recovery of the deoxycoformycin-inhibited enzyme but marked tissue differences were observed."( Deoxycoformycin toxicity in mice after long-term treatment.
Agarwal, RP, 1980
)
1.01
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (1)

RoleDescription
EC 3.5.4.4 (adenosine deaminase) inhibitorAn EC 3.5.4.* (non-peptide cyclic amidine C-N hydrolase) inhibitor that interferes with the action of adenosine deaminase (EC 3.5.4.4).
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (1)

ClassDescription
coformycins
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (4)

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Adenosine deaminaseHomo sapiens (human)Ki0.00240.00000.30887.0000AID1578774; AID1578775; AID1895861; AID33846; AID33968; AID717435
Adenosine deaminase Bos taurus (cattle)Ki1,000,000.00000.00000.48937.0000AID33656
AMP deaminase 3Homo sapiens (human)Ki3.00003.00003.00003.0000AID34757
Adenosine deaminase Plasmodium falciparum (malaria parasite P. falciparum)Ki0.00030.00000.00180.0082AID1578776; AID1578777; AID1578779
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (61)

Processvia Protein(s)Taxonomy
adenosine catabolic processAdenosine deaminaseHomo sapiens (human)
inosine biosynthetic processAdenosine deaminaseHomo sapiens (human)
allantoin metabolic processAdenosine deaminaseHomo sapiens (human)
response to hypoxiaAdenosine deaminaseHomo sapiens (human)
trophectodermal cell differentiationAdenosine deaminaseHomo sapiens (human)
liver developmentAdenosine deaminaseHomo sapiens (human)
placenta developmentAdenosine deaminaseHomo sapiens (human)
germinal center B cell differentiationAdenosine deaminaseHomo sapiens (human)
germinal center formationAdenosine deaminaseHomo sapiens (human)
positive regulation of germinal center formationAdenosine deaminaseHomo sapiens (human)
negative regulation of leukocyte migrationAdenosine deaminaseHomo sapiens (human)
mature B cell apoptotic processAdenosine deaminaseHomo sapiens (human)
negative regulation of mature B cell apoptotic processAdenosine deaminaseHomo sapiens (human)
adenosine catabolic processAdenosine deaminaseHomo sapiens (human)
deoxyadenosine catabolic processAdenosine deaminaseHomo sapiens (human)
AMP catabolic processAdenosine deaminaseHomo sapiens (human)
xenobiotic metabolic processAdenosine deaminaseHomo sapiens (human)
smooth muscle contractionAdenosine deaminaseHomo sapiens (human)
cell adhesionAdenosine deaminaseHomo sapiens (human)
response to inorganic substanceAdenosine deaminaseHomo sapiens (human)
positive regulation of heart rateAdenosine deaminaseHomo sapiens (human)
response to purine-containing compoundAdenosine deaminaseHomo sapiens (human)
calcium-mediated signalingAdenosine deaminaseHomo sapiens (human)
positive regulation of B cell proliferationAdenosine deaminaseHomo sapiens (human)
purine nucleotide salvageAdenosine deaminaseHomo sapiens (human)
GMP salvageAdenosine deaminaseHomo sapiens (human)
T cell differentiation in thymusAdenosine deaminaseHomo sapiens (human)
positive regulation of T cell differentiation in thymusAdenosine deaminaseHomo sapiens (human)
regulation of cell-cell adhesion mediated by integrinAdenosine deaminaseHomo sapiens (human)
B cell proliferationAdenosine deaminaseHomo sapiens (human)
T cell activationAdenosine deaminaseHomo sapiens (human)
penile erectionAdenosine deaminaseHomo sapiens (human)
purine-containing compound salvageAdenosine deaminaseHomo sapiens (human)
amide catabolic processAdenosine deaminaseHomo sapiens (human)
AMP salvageAdenosine deaminaseHomo sapiens (human)
positive regulation of smooth muscle contractionAdenosine deaminaseHomo sapiens (human)
dAMP catabolic processAdenosine deaminaseHomo sapiens (human)
dATP catabolic processAdenosine deaminaseHomo sapiens (human)
adenosine metabolic processAdenosine deaminaseHomo sapiens (human)
inosine biosynthetic processAdenosine deaminaseHomo sapiens (human)
xanthine biosynthetic processAdenosine deaminaseHomo sapiens (human)
alpha-beta T cell differentiationAdenosine deaminaseHomo sapiens (human)
positive regulation of alpha-beta T cell differentiationAdenosine deaminaseHomo sapiens (human)
lung alveolus developmentAdenosine deaminaseHomo sapiens (human)
Peyer's patch developmentAdenosine deaminaseHomo sapiens (human)
embryonic digestive tract developmentAdenosine deaminaseHomo sapiens (human)
negative regulation of inflammatory responseAdenosine deaminaseHomo sapiens (human)
positive regulation of calcium-mediated signalingAdenosine deaminaseHomo sapiens (human)
T cell receptor signaling pathwayAdenosine deaminaseHomo sapiens (human)
positive regulation of T cell receptor signaling pathwayAdenosine deaminaseHomo sapiens (human)
leukocyte migrationAdenosine deaminaseHomo sapiens (human)
negative regulation of adenosine receptor signaling pathwayAdenosine deaminaseHomo sapiens (human)
negative regulation of penile erectionAdenosine deaminaseHomo sapiens (human)
thymocyte apoptotic processAdenosine deaminaseHomo sapiens (human)
negative regulation of thymocyte apoptotic processAdenosine deaminaseHomo sapiens (human)
mucus secretionAdenosine deaminaseHomo sapiens (human)
negative regulation of mucus secretionAdenosine deaminaseHomo sapiens (human)
hypoxanthine salvageAdenosine deaminaseHomo sapiens (human)
adenosine catabolic processAdenosine deaminase Bos taurus (cattle)
cell adhesionAdenosine deaminase Bos taurus (cattle)
nucleotide metabolic processAdenosine deaminase Bos taurus (cattle)
purine ribonucleoside monophosphate biosynthetic processAdenosine deaminase Bos taurus (cattle)
inosine biosynthetic processAdenosine deaminase Bos taurus (cattle)
AMP catabolic processAMP deaminase 3Homo sapiens (human)
IMP salvageAMP deaminase 3Homo sapiens (human)
AMP metabolic processAMP deaminase 3Homo sapiens (human)
IMP biosynthetic processAMP deaminase 3Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (7)

Processvia Protein(s)Taxonomy
adenosine deaminase activityAdenosine deaminaseHomo sapiens (human)
protein bindingAdenosine deaminaseHomo sapiens (human)
zinc ion bindingAdenosine deaminaseHomo sapiens (human)
deaminase activityAdenosine deaminaseHomo sapiens (human)
2'-deoxyadenosine deaminase activityAdenosine deaminaseHomo sapiens (human)
adenosine deaminase activityAdenosine deaminase Bos taurus (cattle)
protein bindingAdenosine deaminase Bos taurus (cattle)
zinc ion bindingAdenosine deaminase Bos taurus (cattle)
2'-deoxyadenosine deaminase activityAdenosine deaminase Bos taurus (cattle)
AMP deaminase activityAMP deaminase 3Homo sapiens (human)
protein bindingAMP deaminase 3Homo sapiens (human)
metal ion bindingAMP deaminase 3Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (11)

Processvia Protein(s)Taxonomy
lysosomeAdenosine deaminaseHomo sapiens (human)
cytosolAdenosine deaminaseHomo sapiens (human)
plasma membraneAdenosine deaminaseHomo sapiens (human)
external side of plasma membraneAdenosine deaminaseHomo sapiens (human)
cell surfaceAdenosine deaminaseHomo sapiens (human)
membraneAdenosine deaminaseHomo sapiens (human)
cytoplasmic vesicle lumenAdenosine deaminaseHomo sapiens (human)
anchoring junctionAdenosine deaminaseHomo sapiens (human)
cytosolAdenosine deaminaseHomo sapiens (human)
external side of plasma membraneAdenosine deaminaseHomo sapiens (human)
lysosomeAdenosine deaminase Bos taurus (cattle)
cytoplasmic vesicle lumenAdenosine deaminase Bos taurus (cattle)
anchoring junctionAdenosine deaminase Bos taurus (cattle)
extracellular regionAMP deaminase 3Homo sapiens (human)
cytosolAMP deaminase 3Homo sapiens (human)
secretory granule lumenAMP deaminase 3Homo sapiens (human)
ficolin-1-rich granule lumenAMP deaminase 3Homo sapiens (human)
cytosolAMP deaminase 3Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (14)

Assay IDTitleYearJournalArticle
AID33661Binding affinity towards calf spleen adenosine deaminase was determined2004Journal of medicinal chemistry, Feb-12, Volume: 47, Issue:4
Inhibition of adenosine deaminase by novel 5:7 fused heterocycles containing the imidazo[4,5-e][1,2,4]triazepine ring system: a structure-activity relationship study.
AID717435Inhibition of adenosine deaminase2012Bioorganic & medicinal chemistry letters, Dec-01, Volume: 22, Issue:23
Investigations into specificity of azepinomycin for inhibition of guanase: discrimination between the natural heterocyclic inhibitor and its synthetic nucleoside analogues.
AID1578776Inhibition of Plasmodium falciparum N-terminal thrombin cleavable His6-tagged ADA expressed in Escherichia coli BL21 assessed as reduction in formation of inosine using adenosine as substrate2019Journal of medicinal chemistry, 09-26, Volume: 62, Issue:18
Plasmodium Purine Metabolism and Its Inhibition by Nucleoside and Nucleotide Analogues.
AID33656Binding affinity (Ki) at calf intestinal adenosine deaminase.1992Journal of medicinal chemistry, Oct-30, Volume: 35, Issue:22
Adenosine deaminase inhibitors. Synthesis and biological evaluation of C1' and nor-C1' derivatives of (+)-erythro-9-(2(S)-hydroxy-3(R)-nonyl)adenine.
AID33658Binding affinity against calf intestine adenosine deaminase enzyme; 10E-11 to 10e-12 M1984Journal of medicinal chemistry, Mar, Volume: 27, Issue:3
Adenosine deaminase inhibitors. Synthesis of deaza analogues of erythro-9-(2-hydroxy-3-nonyl)adenine.
AID1578774Inhibition of human erythrocytes ADA assessed as reduction in formation of inosine using adenosine as substrate2019Journal of medicinal chemistry, 09-26, Volume: 62, Issue:18
Plasmodium Purine Metabolism and Its Inhibition by Nucleoside and Nucleotide Analogues.
AID1578775Inhibition of human erythrocytes ADA assessed as equilibrium dissociation constant by measuring reduction in formation of inosine using adenosine as substrate2019Journal of medicinal chemistry, 09-26, Volume: 62, Issue:18
Plasmodium Purine Metabolism and Its Inhibition by Nucleoside and Nucleotide Analogues.
AID33968The compound was tested in vitro for inhibition of human erythrocytic adenosine deaminase1983Journal of medicinal chemistry, Oct, Volume: 26, Issue:10
Adenosine deaminase inhibitors. Synthesis and biological evaluation of (+/-)-3,6,7,8-tetrahydro-3-[(2-hydroxyethoxy)methyl]imidazo[4,5-d] [1,3]diazepin-8-ol and some selected C-5 homologues of pentostatin.
AID227718Binding energy by using the equation deltaG obsd = -RT ln KD1984Journal of medicinal chemistry, Dec, Volume: 27, Issue:12
Functional group contributions to drug-receptor interactions.
AID34757Inhibition of recombinant human E-type adenylate deaminase2001Journal of medicinal chemistry, Feb-15, Volume: 44, Issue:4
AMP deaminase inhibitors. 5. Design, synthesis, and SAR of a highly potent inhibitor series.
AID1578779Inhibition of Plasmodium falciparum ADA assessed as reduction in formation of ammonia using adenosine as substrate incubated for 15 mins by spectrophotometric analysis2019Journal of medicinal chemistry, 09-26, Volume: 62, Issue:18
Plasmodium Purine Metabolism and Its Inhibition by Nucleoside and Nucleotide Analogues.
AID1578777Inhibition of Plasmodium falciparum N-terminal thrombin cleavable His6-tagged ADA expressed in Escherichia coli BL21 assessed as equilibrium dissociation constant by measuring reduction in formation of inosine using adenosine as substrate2019Journal of medicinal chemistry, 09-26, Volume: 62, Issue:18
Plasmodium Purine Metabolism and Its Inhibition by Nucleoside and Nucleotide Analogues.
AID33846Compound was evaluated for the inhibition of adenosine deaminase1981Journal of medicinal chemistry, Dec, Volume: 24, Issue:12
Adenosine deaminase inhibitors. Conversion of a single chiral synthon into erythro- and threo-9-(2-hydroxy-3-nonyl)adenines.
AID1895861Binding affinity to ADA (unknown origin) assessed as inhibition constant2021European journal of medicinal chemistry, Dec-15, Volume: 226Zinc enzymes in medicinal chemistry.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (480)

TimeframeStudies, This Drug (%)All Drugs %
pre-1990419 (87.29)18.7374
1990's34 (7.08)18.2507
2000's19 (3.96)29.6817
2010's6 (1.25)24.3611
2020's2 (0.42)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 19.49

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index19.49 (24.57)
Research Supply Index6.22 (2.92)
Research Growth Index4.07 (4.65)
Search Engine Demand Index23.28 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (19.49)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials10 (2.02%)5.53%
Reviews26 (5.26%)6.00%
Case Studies35 (7.09%)4.05%
Observational0 (0.00%)0.25%
Other423 (85.63%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]